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Abstract
Introduction: A majority of familial frontotemporal lobar dementia and amyotrophic lateral sclerosis cases are
associated with a large repeat expansion in a non-coding region of the C9ORF72 gene. Currently, little is known about
the normal function and the expression pattern of the C9ORF72 protein. The aims of this study were to characterize
the expression pattern and cellular localization of the three reported mouse isoforms of C9orf72, over a developmental
time-course in primary cultured cortical neurons and brain tissue from C57BL/6 mice.
Results: We demonstrated that the different isoforms of C9ORF72 at the mRNA and protein level undergo alterations in
expression during development and into adulthood. Cellular fractionation and immunofluorescence demonstrated that
levels of nuclear and cytoplasmic expression of isoforms changed significantly over the time course. Additionally,
immunofluorescence studies showed C9ORF72 labeling as puncta throughout neurons, extending beyond the
microtubule cytoskeleton into actin-rich structures such as filopodia and growth cones. Finally, synaptosome preparations
demonstrated the presence of C9ORF72 isoform 1 in synaptic-rich fractions from adult mouse brain.
Conclusion: In summary, the presence of C9ORF72 as puncta and within synaptic-rich fractions may indicate
involvement at the synapse and differential expression of isoforms in nuclei and cytoplasm may suggest distinct roles for
the isoforms. Determining the physiological role of C9ORF72 protein may help to determine the role it plays in disease.
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Introduction
Frontotemporal lobar dementia (FTLD) and amyo-
trophic lateral sclerosis (ALS) are progressive neurode-
generative disorders, which due to their overlapping
features, are now thought to represent two ends of a dis-
ease spectrum [17]. In 2011, two independent groups
identified the largest genetic cause of FTLD and ALS as a
repeat expansion of the hexanucleotide sequence
GGGGCC in the C9ORF72 gene [4, 25]. This expansion
occurs in a non-coding region of chromosome 9. It is cur-
rently unknown how the repeat expansion contributes to
FTLD and ALS, although several mechanisms have been
proposed, including potential unconventional translation
of the repeated sequence (repeat-associated non-ATG ini-
tiated translation) leading to intracellular accumulations
of dipeptide repeat proteins [1, 23], and the sequestration
of RNA binding proteins into RNA foci, causing RNA
dysfunction [4, 27]. Alternatively, the hexanucleotide ex-
pansion may result in haploinsufficiency due to reduced
expression of C9ORF72 transcripts [2, 4, 5, 33, 34, 37].
While pathological features of C9ORF72-associated
disease, such as TDP-43 aggregates, dipeptide repeat
protein expression and RNA foci, are under intense in-
vestigation regarding their role in disease, to date, less
attention has been paid to the normal expression and
function of the encoded protein, C9ORF72. Elucidating
the expression, localization and function of this protein
in neural cells may contribute further to knowledge re-
garding how the repeat expansion is associated with
neurodegenerative changes.
In humans, alternative splicing of three RNA tran-
script variants from the C9ORF72 gene produces two
different isoforms of the C9ORF72 protein (Fig. 1a) [25].
Transcript variants 1 and 3 encode a 481 amino acid
protein and variant 2 encodes a 222 amino acid protein
[4]. In mice, there are 3 protein-coding regions reported
of 481 (isoform 1), 420 (isoform 2) and 317 (isoform 3)
amino acids, likely encoding at least 3 different protein
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isoforms (Fig. 1b). However, the roles of the encoded pro-
teins have not been well characterized. We have previ-
ously demonstrated a role for C9ORF72 in trafficking [7]
which was in line with previous studies [16]. C9ORF72 is
involved in endosomal trafficking via Rab-dependent
pathways. Rab proteins are part of the Rab-GDP/GTP ex-
change factor family (Rab-GEF) (as reviewed in [29]) that
mediate all membrane trafficking events between organ-
elles. We provided the first experimental evidence for this,
when we established that C9ORF72 regulates endocytosis
and autophagy [7].
Other studies have examined the expression of the
C9orf72 gene using a transgenic mouse model harboring a
targeted LacZ insertion [32]. This study observed C9orf72
in neuronal and non-neuronal cells within the central
nervous system (CNS). Recently, the effect of ablating the
3 isoforms of C9ORF72 protein from neurons and glia has
been examined, demonstrating a reduction in body weight
but no motor neuron degeneration or motor deficits [15].
This suggests that complete lack of C9ORF72 throughout
development and adulthood is not sufficient to cause a
motor neuron disease phenotype in mice.
Several studies have examined the expression of
C9ORF72 in human tissue [3, 4, 11, 13, 28, 30] and cell
lines [11, 25] using a variety of commercial antibodies.
However, there has been a lack of consensus about the
localization of C9ORF72 across these studies. Some in-
vestigations have described coarse punctate expression
within the hippocampus, suggestive of synaptic termi-
nals [3, 13, 26, 28]. Recently, Xiao and colleagues [37]
generated antibodies specific to the two human C9ORF72
isoforms. They demonstrated diffuse cytoplasmic and
‘speckled’ localization of the long isoform, as well as
localization of the short isoform to the nuclear membrane.
This is in line with our previous investigation which dem-
onstrated a nuclear and punctate pattern of expres-
sion (typical of vesicles) of C9ORF72 in vitro in both SH-
SY5Y cells and in primary cultured cortical neurons [7].
The current study examined the expression of
C9ORF72 in the mouse CNS over development in vivo
and in vitro in order to provide information about its ex-
pression and cellular localization during neurite out-
growth, neuron maturation and synapse formation. This
investigation demonstrated that expression of C9ORF72
mRNA and protein differ over a developmental time
course, are expressed in both nuclear and cytoplasmic
fractions in an isoform specific manner, and that the large
isoform may be present in synaptic fractions.
Materials and methods
Animals
C57BL/6 mice were utilized in this study. All experiments
involving animals were approved by the University of
Tasmania Animal Ethics Committee (A12780) and were in
accordance with the Australian Guidelines for the Care and
Use of Animals for Scientific Purposes.
Tissue preparation
For molecular biology analysis, combined neocortical
and hippocampal tissue was harvested from mice at em-
bryonic day (E) 18, postnatal day (P) 1, P7, P14, P28 and
P56 (for western blot) (n = 4 mice per time-point) and
P1, P7 and P56 (for real time qPCR) (n = 4 mice per time-
point). Tissue was processed as previously described [18].
Fig. 1 Schematic overview of human and mouse C9ORF72 transcripts and encoded proteins. Protein coding regions for transcript variants
(V1 to 3) are indicated in light blue for human (a) and dark blue for mouse (b) as well as size of encoded proteins. Non-coding regions are
indicated in red and location of the G4C2 repeat expansion in yellow.
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For immunohistochemical analysis, animals were termin-
ally anaesthetized with sodium pentobarbitone (140 mg/kg)
and transcardially perfused with 4 % paraformaldehyde.
Brains were immediately dissected, post-fixed overnight in
paraformaldehyde and then cryoprotected as previously de-
scribed [19]. Serial 40 μm coronal sections were cut on a
cryostat (Leica CM 1850). For each mouse at each time
point, four regularly spaced sections were examined from
the rostral to caudal cortex corresponding to bregma
0.98 mm to −1.82 mm (in adult tissue) according to the
stereotaxic mice atlas [10]. Antigen retrieval was carried
out prior to immunohistochemistry using citric acid,
pH 6.0, in a pressure cooker for 14 min.
Protein extraction and western blot analysis
Protein from combined cerebral cortex and hippocampus
was extracted with RIPA Buffer (Sigma Aldrich) contain-
ing a cocktail of protease inhibitors (Roche). Protein ex-
tract was then placed at 4 °C for 30 min, centrifuged at
13,000 rpm for 20 min and supernatant stored at −80 °C.
Denatured proteins samples (15 μg) from each time-
point were electrophoresed into 10 % SDS-PAGE gels
(BioRad), transferred to PVDF membranes (BioRad) and in-
cubated in primary antibodies, C9ORF72 (1:500, Santa
Cruz, sc-138763) and GAPDH (1:7000, Millipore), over-
night (Table 1). A corresponding anti-rabbit or anti-mouse
horseradish peroxidase (HRP)-conjugated secondary anti-
body (1:7000; Amersham) was used, as described previously
[18]. GAPDH (1:7000, Millipore) was used as a loading
control and band intensity was measured as the integrated
intensity using ImageJ software (v1.4; NIH), and normalized
with respect to the loading controls. Three experimental re-
peats were carried out.
Nuclear and cytoplasmic fractionation
Nuclear and cytoplasmic protein extractions were pre-
pared from right hemispheres (excluding olfactory bulbs
and cerebellum) of fresh P1, P7, P56 brains using the
NE-PER kit (Thermo Fisher Scientific) according to
manufacturer instructions. Denatured protein samples
were electrophoresed as described above. Fraction purity
was confirmed by labeling with HDAC2 (1:700; Abcam)
for nuclear fractions and GAPDH (as above) for cytoplas-
mic fractions. Membranes were also incubated with
C9ORF72 antibody (as above). Densitometry analysis of
bands was carried out using ImageJ. Results were
normalized to total protein. Three experimental repeats
were carried out.
Synaptosome preparation
Synaptosomes were prepared as described previously [6,
22] with some modifications. Briefly, P56 mice (n = 4) were
anaesthetized and perfused with sucrose buffer (0.32 M su-
crose, 1 mM ethylenediaminetetraacetic acid, 5 mM dithio-
threitol, pH 7.4). Whole brains were harvested and
homogenized at 4 °C with a teflon-glass homogenizer using
12 strokes with 9:1 ratio of sucrose buffer supplemented
with a protease cocktail inhibitor (Roche) to 1 g of tissue.
Homogenate was centrifuged at 1000xg for 10 min at 4 °C.
The resulting pellet containing mostly nuclei was removed
and the supernatant was layered onto a discontinuous gra-
dient consisting of 3, 10, 15 and 23 % (vol/vol) Percoll (GE
Healthcare). Tubes were then centrifuged at 31,000xg for
8 min at 4 °C in a Sorvall WX Ultra90 (70.I TI rotor).
The contents of the resulting fractions have been char-
acterized previously [6, 31]. The resulting purified frac-
tions were collected and protein was extracted in RIPA
buffer for western blotting. Denatured protein samples
(15 μg) were electrophoresed as described above. Mem-
branes were probed with C9ORF72 antibody, along with
synaptic markers: synaptophysin (1:5000, Millipore),
PSD-95 (1:1000, Abcam), GAD67 (1:2500, Millipore);
and GFAP (1:1000, NeuroMAB) as a marker of glia.
RNA isolation and RT-PCR analysis
Total RNA from combined cerebral cortex and hippocam-
pus tissue at the time-points P1, P7 and P56 (n = 4 mice
per time point) was isolated using the RNeasy Mini Kit
(Qiagen), according to the manufacturer’s instructions
and complementary DNA (cDNA) was synthesized from
DNase-treated RNA (1 μg) as described previously [8].
To semi-quantitatively analyse C9orf72 gene expression,
quantitative PCR (qPCR) analysis was conducted as previ-
ously described [9]. Before relative quantification, C9orf72
gene was subjected to a serial dilution assay to determine
the optimum detection range of Ct values, with a Ct thresh-
old of 35 for undetectable mRNA levels of expression. Rela-
tive quantitation of C9orf72 mRNA isoforms per time point
was performed using 25 ng of reverse-transcribed total
RNA, 20 pmol/ml of both sense and antisense primers and
the SYBR Green PCR master mix (Applied Biosystems) in a
final reaction volume of 10 μl. The reactions were run on
Table 1 List of qPCR primers
Gene name Forward primer Reverse primer Accession number
C9orf72 isoform 1 5’- CCCACCATCTCCTGCTGTTG-3’ 5’-GTAAGCAAAGGTAGCCGCCA-3’ NM_001081343.1
C9orf72 isoform 2 5’- TGGAAGATCAGGGTCAGAGT-3’ 5’- GCAAGCAGCTCCATTACAGG-3’ XM_006538294.1
C9orf72 isoform 3 5’-CTTTCCTTGCACAGTTCCTCC-3’ 5’- TCATCCTCGATGTACTTGATTAGTG-3’ XM_006538292.2
Primers used for qPCR analysis of the 3 C9orf72 isoforms including primer sequence (forward and reverse sequence respectively) and GenBank accession number
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an LightCycler® 480 System (Roche) according to the man-
ufacturer’s instructions. To standardize the amount of sam-
ple cDNA added to the reaction, amplification of
endogenous control β-Actin (primer sequence obtained
from Gonzalez-Fernandez and colleagues [12]) were in-
cluded in a separate well as a real-time reporter. Primer ef-
ficiency was calculated (Additional file 1: Figure S1a), and
at the end of each run, melting curve profiles were per-
formed to confirm amplification of specific transcripts
(Additional file 1: Figure S1b). Relative quantification for
each gene was performed by the ΔΔCt method [20].
All primers were designed using NCBI/Primer-
BLAST software (Table 1). Primers were designed to
amplify the different isoforms of the C9orf72 mouse
ortholog (3111004O21Rik). As C9orf72 isoforms 2 and
3 are contained within isoform 1, fold change in the
mRNA expression of isoform 2 and 3 were calculated
as the increment with respect to the expression levels
of isoform 1.
Cell culture
Primary dissociated cortical cultures were prepared as
previously described [14] using standard culture tech-
niques with slight modifications. Briefly, neocortical tis-
sue was harvested from E15.5 C57BL/6 mice and
enzymatically dissociated in 0.0125 % trypsin for 4 min,
prior to plating. Cells were plated onto poly L-lysine
(Sigma Aldrich) coated 12 mm coverslips in 24 well plates
at a density of 30,000 viable cells per coverslip. Cells were
grown in an initial plating media consisting of Neuroba-
sal™ medium (Gibco), 2 % B27 supplement, 10 % fetal calf
serum (Gibco), 0.5 mM glutamine, 25 mM glutamate and
1 % antibiotic/antimycotic (Gibco). Medium was replaced
on the following day with subsequent growth media con-
sisting of initial media without the fetal calf serum and
glutamate, and half the media was replenished weekly with
fresh subsequent growth medium. Cultures were grown at
37 °C and 5 % CO2. Neurons were fixed with 4 % para-
formaldehyde (Sigma Aldrich) at 1, 3, 7, 14 and 21 days
in vitro (DIV) (n > 5 cultures per time-point).
Immunofluorescence
Cultured cells and brain sections were washed 3x10 mi-
nutes in 0.01 M PBS followed by serum-free protein
block (Dako) for 15 min at room temperature (RT). Im-
munofluorescence labeling was carried out for both
cultured cells and brain tissue following standard pro-
cedures using antibodies against C9ORF72 (as above),
β-III Tubulin (1:5000, Promega) and MAP2 (1:1000,
Millipore) diluted in PBS with 0.6 % Triton-X-100 and
incubated at RT overnight. Samples were incubated in
secondary antibodies (AlexaFluor, Invitrogen Probes) for
2 h at RT, followed by incubation with the nuclear stain
DAPI (5 μg/ml; Molecular Probes®, Life Technologies), for
5 min at RT. Immunoreactivity was visualized and cap-
tured using a Leica (Germany) DM BL2 upright fluores-
cence microscope. For the purpose of illustration, images
were then adjusted for brightness and contrast using
Adobe Photoshop CS6 (v 13).
Specificity of immunoreactivity was confirmed by two
methods. Both brain sections and cultured cells were ex-
amined for non-specific labeling after processing without
primary antibody. Additionally, tissue from P56 brain
and seven DIV cultures were incubated with C9ORF72
antibody combined with seven times excess of C9ORF72
peptide (sc-138763 P; Santa Cruz).
Statistical analyses
All statistical analysis was performed using GraphPad
Prism software (version 6.0) and p-values with p < 0.05
(CI 95 %) considered significant. Values were reported as
the mean ± standard error (SEM). Data from real time
PCR studies were compared using a one-way ANOVA
followed by a Tukey post-hoc and t-tests for a point-to-
point comparison. Data from western blots were com-
pared using a two-way ANOVA followed by Tukey or
Sidak post-hoc comparisons.
Results
Cellular pattern of C9ORF72 protein changes over
development of mouse cortex
This study utilized the commercially available anti-human
C9ORF72 antibody raised against amino acid residues 165
to 215 of C9ORF72 protein, which is contained within the
sequence of all three mouse C9ORF72 isoforms. We have
previously shown a decrease in labeling in a western blot
with the antibody following treatment with C9ORF72
short interfering RNA (siRNA) [7]. To further characterize
the specificity of immunolabeling, the C9ORF72 antibody
was preadsorbed with recombinant peptide. Immunola-
beling of tissue sections from P56 mice (Additional file
2: Figure S2a) and cultured cortical neurons at 7 DIV
(Additional file 2: Figure S2b) with preadsorbed
C9ORF72 demonstrated that, relative to non-adsorbed
antibody, there was a large reduction in immunolabeling
(Additional file 2: Figure S2).
We next determined the expression or localization of
C9ORF72 over a developmental time course from E18
to P56 in mice, which covers periods of neurite out-
growth and synapse development [24, 36]. To determine
how C9ORF72 localization changes over development,
40 μm coronal tissue sections from mice at ages E18, P1,
P14, P28 and P56 were immunolabeled with C9ORF72
antibody along with the neuronal somatodendritic
marker, MAP2. At both E18 (data not shown) and P1,
there was strong labeling for C9ORF72 in discrete
puncta throughout the neuropil (Fig. 2a) but little somal
immunoreactivity was present. At P7, there was distinct
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somal and nuclear expression, which was both diffuse
and punctate in many MAP2-immunoreactive cells
throughout the cortex and hippocampus (Fig. 2b), con-
firming the presence of C9ORF72 in neurons. At P14,
P28 and P56, cytoplasmic labeling continued with appar-
ent lower expression in nuclei (Fig. 2c). Punctate labeling
was less distinct than at P1 and P7 (Fig. 2a and b).
Temporal expression of C9ORF72 isoforms over
development
We evaluated the temporal mRNA expression pattern of
C9orf72 isoforms (C9orf72- 1, 2 and 3; Fig. 1). As shown
in Fig. 3a, the mRNA encoding for all C9orf72 isoforms
were detected in combined cerebral cortex and hippo-
campus tissue at all time-points P1, P7 and P56. Isoform
1 was significantly (p < 0.05) higher at P1 compared to
P7 and P56 (Fig. 3a) and, similarly, the expression of iso-
form 2 was significantly (p < 0.05) higher at P56 relative
to the other time points tested (Fig. 3a). There were no
changes in the mRNA expression levels of isoform 3
over development (Fig. 3a). Next, by western blot ana-
lysis, we evaluated the temporal protein expression of
C9ORF72 protein-coding regions (481, 420 and 317
amino acids), which correspond to predicted protein size
isoforms of approximately 55, 50 and 35 kDa. Western
blots of combined cerebral cortex and hippocampus tis-
sue demonstrated that the Santa Cruz C9ORF72 anti-
body labeled the three predicted protein isoforms at 55,
50 and 35 kDa at all the time points (Fig. 3b). Moreover,
we also detected additional bands at 110 kDa. The iden-
tity of this band remains unknown.
Subcellular localization of C9ORF72 over development
To further investigate the differential nuclear and cyto-
plasmic localization of C9ORF72 over development in
vivo, nuclear and cytoplasmic protein extractions were
performed at E18, P1, P7 and P56. Purity of the nuclear
Fig. 2 Localization of C9ORF72 during development in vivo. a At P1, C9ORF72 (red) had punctate localization throughout the neuropil (arrows).
b At P7, C9ORF72 labeling was present within nuclei (arrowheads) of neuronal cells (MAP2, green) and as strong puncta within cytoplasm and
neuropil (arrows). c At P56, C9ORF72 labeling was present in the neuropil as puncta (arrows) and was localized to the cytoplasm surrounding
nuclei (DAPI, arrowheads) Scale bar: 10 μm
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and cytoplasmic extractions was confirmed with HDAC
2 and GAPDH antibodies with HDAC2 being higher in
the nuclear samples and GAPDH being higher in the
cytoplasmic samples (Fig. 4a). As in non-fractionated
samples, western blot analysis of C9ORF72 showed pro-
tein bands at approximately 55, 50 and 35 kDa. The
55 kDa protein was significantly (p < 0.05) higher in the
nuclear fractions compared to cytoplasmic fractions
(Fig. 4b). Post hoc tests showed that at E18 and P1 there
was significantly (p < 0.05) more of the 55 kDa protein
in nuclear fractions compared to cytoplasmic fractions.
Post hoc tests also showed that within nuclear fractions,
there was significantly (p< 0.05) more 5 kDa protein at
E18 compared to P56. There were no significant differ-
ences in cytoplasmic expression of the 55 kDa protein
over the time course. There were also no differences in
localization of the 50 kDa protein over the time course
(Fig. 4b). The 35 kDa protein was significantly higher in
the cytoplasmic fractions compared to nuclear fractions
(p < 0.05) (Fig. 4b). Post hoc tests showed that, at E18
and P1, there was significantly (p < 0.05) more of the
55 kDa protein in cytoplasmic fractions compared to
nuclear. Post hoc tests also showed that within cytoplas-
mic fractions there was significantly (p < 0.05) more
35 kDa protein at E18, P1 and P7 compared to P56.
There were no significant differences in nuclear expres-
sion of the 35 kDa protein over the time course. These
results suggest that C9ORF72 protein isoforms were dif-
ferentially expressed in cellular compartments over
development.
C9ORF72 is present in synaptosome preparations
Our results showed that C9ORF72 has punctate
localization in the neuropil, however, it is unclear if it is
present in synapses. To address this, we performed sub-
cellular fractionation on P56 mouse brain tissue to iso-
late synaptosome fractions according to the methods of
Dunkley, Jarvie and Robinson [6]. The content of each
resulting fraction have been characterized previously
[6, 31]. F1 contains unidentified membranous material
[6], F2 contains predominantly re-sealed plasma mem-
branes from glial cells [31]. F3 and F4 contain purified
synaptosomes and these fractions were combined [6].
To confirm the purity of the fractions, western blotting
Fig. 3 Expression of C9ORF72 isoforms over development. a Relative expression of C9orf72 isoforms 1, 2 and 3 mRNA in combined cerebral
cortex and hippocampus of C57Bl/6 mice. Isoform 1 was significantly (p < 0.05) higher at P1 compared to P7 and P56 and isoform 2 was
significantly (p < 0.05) higher at P56 compared to P1 and P7. b Western blot of C9ORF72 expression in mouse tissue over development. Bands
corresponding to reported isoforms of C9ORF72 were present at 55, 50 and 35 kDa (b). Additional bands at 110 and 50 kDa were also present.
GAPDH was used as a loading control. Values represent mean ± standard error. *p < 0.05 P1 and P7 vs. P56
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was carried out with a range of antibodies. GFAP was used
as a glia marker and was most abundant in F2 (Fig. 5). As
expected, synaptophysin, PSD95 and GAD67 were most
abundant within the F3/F4 fraction (Fig. 5). Only the
55 kDa protein band of C9ORF72 was observed within
C9ORF72-positive fractions, and was most abundant
within F3/F4 fractions where other synaptic proteins were
found. It was also present at low levels in F2.
C9ORF72 is expressed in nuclei and neurites of cultured
cortical neurons
For a more detailed examination of the localization of
C9ORF72 in neuronal soma and neurites, immunocyto-
chemistry was performed in cultured cortical neurons
fixed at 1, 3 and 7 DIV (during neurite outgrowth) and
14 and 21 DIV (during synaptogenesis and maturity).
Neurons were labeled with C9ORF72 along with neur-
onal cytoskeletal markers βIII-tubulin and MAP2 and
the F-actin stain, phalloidin. At 1 and 3 DIV, C9ORF72
labeling was present in the cell soma, excluding the nu-
cleus, and throughout the neurites as demonstrated by
co-labeling with βIII-tubulin (Fig. 6a). C9ORF72 also ex-
tended into the actin cytoskeleton, including within
growth cones and filopodia extending from the soma
and down the length of neurites, as demonstrated by co-
labeling with phalloidin (Fig. 6b).
From 7 DIV, immunolabeling for C9ORF72 increased
in the soma and a large proportion of cells had high nu-
clear expression of the protein, accompanied by bright
puncta in the soma (data not shown). Similar cellular
localization was observed at 14 DIV with bright vesicular
labeled puncta more prominent in, but not restricted to,
neurons with nuclear expression of C9ORF72 (Fig. 6c). A
smaller proportion of neurons had more diffuse immunola-
beling which was present in less intensely stained puncta in
the cytoplasm and neurites (axons and dendrites, demon-
strated by MAP2 co-labeling) in cells with nuclear and
non-nuclear labeling. Immunolabeling of C9ORF72 was
similar at 21 DIV. These results show that C9ORF72 was
present throughout the microtubule cytoskeleton including
throughout the axon, soma and dendritic arbor as well as
within actin-rich structures such as growth cones and
filopodia.
Discussion and conclusions
In this study, we have examined the expression of
C9ORF72 by multiple biochemical and molecular bio-
logical analyses conducted both in vivo and in vitro.
Results from these investigations demonstrated that
C9ORF72 undergoes alterations in cellular expression
and localization throughout the time course analyzed,
which may reflect differential expression of isoforms
that are present in specific locations. Furthermore
C9ORF72 is found in synaptic-rich cellular fractions.
In order to gain some insight into the function of
C9ORF72 protein, we examined whether the expression
level was altered throughout development. Neuronal de-
velopment involves a number of different processes and
therefore alterations in the expression or localization of
proteins during development may indicate a role in
these processes. Our results suggest that there are alter-
ations in the cellular localization of C9ORF72 protein as
well as in the expression pattern of the isoforms over
Fig. 4 Expression of C9ORF72 in nuclear and cytoplasmic protein
fractions over development. a Representative western blot of C9ORF72
in nuclear and cytoplasmic fractions from E18, P1, P7, and P56 mouse
brain. HDAC2 and GAPDH were used to demonstrate nuclear and
cytoplasmic fractions respectively. C9ORF72 isoforms were present at
differing levels and in specific fractions throughout the time course.
b Relative quantitation of C9ORF72 isoform expression in nuclear and
cytoplasmic fractions over the time course. Overall, the 55 kDa protein
was significantly (p < 0.05) increased within nuclear fractions compared
to cytoplasmic fractions and specifically at E18 and P1 compared to
P56 (p < 0.05). Within nuclear fractions, the 55 kDa protein was
significantly (p < 0.05) increased at P1 compared to P56. There were no
significant differences in nuclear and cytoplasmic expression for the
50 kDa band. Overall, the 35 kDa band was significantly (p < 0.05)
increased within cytoplasmic fractions compared to nuclear fractions
and specifically at E18 compared to P56 (p< 0.05). Within cytoplasmic
fractions, the 35 kDa protein was significantly increased (p < 0.05) at
E18, P1 and P7 compared to P56. Values represent mean ± standard
error. *p < 0.05 nuclear vs. cytoplasmic at E18 and P1. + p < 0.05 E18
vs. P56 (nuclear for 55 kDa bad, cytoplasmic for 35 kDa band). # p< 0.05
P1 vs. P56 (nuclear for 55 kDa band, cytoplasmic for 35 kDa band)
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time. C9ORF72 was detected prenatally, consistent with
previous studies looking at the protein in mouse tissue
[15]. C9ORF72 was also observed in adult as well as in
embryonic and larval stages in zebrafish [2, 15]. A tran-
scription expression study of the mouse ortholog of
C9orf72 found that it was only detectable from P1 in the
CNS where it increased gradually until P60 [32]. Koppers
[15] suggested these differences could be explained by a
failure of the heterozygous LacZ reporter mice used in this
study to detect the low levels of gene expression present
prenatally.
C9ORF72 isoforms were differentially expressed be-
tween the nucleus and cytoplasm. Western blot analysis
of nuclear and cytoplasmic protein fractions showed that
the 55 kDa band was predominantly nuclear, the 35 kDa
band was predominantly cytoplasmic and the 50 kDa
band was expressed similarly in both fractions. The ex-
pression of mRNA for isoform 1 was higher at P1 than
in adult tissue corresponding with higher protein expres-
sion of isoform 1 at P1. The higher expression of isoform
1 during these developmental timepoints is consistent
with the strong immunohistochemical labeling of
C9ORF72 in mouse tissue in postnatal tissue and the
localization of C9ORF72 to nuclei at P7. At P56 there was
an increase in isoform 2 mRNA compared to P1 and P7.
However, this increase in mRNA content was not reflected
at the protein level, where isoform 2 protein was signifi-
cantly higher at early timepoints. These discrepancies may
be explained by differences in mechanisms involved in the
post-transcriptional regulation, or repression of translation
of isoform 2 mRNA in adulthood. A recent study by Xiao
and colleagues [37] found differential localization of
human C9ORF72 isoforms. The human short isoform
(approximately 25 kDa) was localized to the nuclear mem-
brane and the long isoform (approximately 55 kDa) was lo-
calized to cytoplasm with diffuse and punctate expression.
The identity of the 110 kDa band labeled by C9ORF72
is unknown. These bands have been observed in previ-
ous studies [25] and also in our western blots from pri-
mary cell culture (data not shown). As the characteristic
labeling of C9ORF72 was reduced following preadsorb-
tion, we speculate that there is a possibility that it could
be a dimer of the 55 kDa band resistant to the reducing
agents used in the western blot protocol. Further studies
are required to investigate these bands.
Throughout all time points in the current study,
C9ORF72 had a punctate pattern of immunolabeling,
which is consistent with other studies describing expres-
sion of this protein. In mice, synaptogenesis ranges from
the first to third weeks of postnatal life [24]. It is there-
fore plausible that, in the current study, the presence of
strongly labeled puncta during this time and reports of
diffuse cytoplasmic and punctate labeling from other
studies [3, 13, 26, 28, 37] suggest involvement of
C9ORF72 at the synapse. Only the 55 kDa form of
C9ORF72 was in synaptic-rich fractions in the synapto-
some preparations, perhaps indicating a specific role of
isoform 1 at synapses. This is also consistent with higher
expression of isoform 1 at early postnatal timepoints.
It is unknown why specific populations of cells are vul-
nerable to degeneration in diseases such as FTLD and
ALS. In this study, we showed C9ORF72 expression in
neurites and the neuropil. Previous studies have found
C9ORF72 within dystrophic neurites within plaques of
AD brains and within swollen neurites in the hippocam-
pus of both AD and non-AD brains [26], suggesting that
Fig. 5 Expression of C9ORF72 in synaptosome preparations from mouse brains. Figure shows representative western blots with results from 2
animals for each marker (indicated by 1 and 2 on figure). The 55 kDa isoform of C9ORF72 was present in the combined F3/F4 fractions which
contain synaptosomes. C9ORF72 expression was low in fraction F1, containing membranes, and F2 containing myelin, membranes and glia.
Unfractionated brain at P56 was also included. Purity of fractions was determined by labeling with GFAP (F2) and synaptic markers,
synaptophysin, PSD-95 and GAD67 (F3/F4)
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it is present in neurites. Additionally, the protein is ob-
served within swollen axons in the spinal cord ventral
gray matter [30]. Motor deficits and abnormal motor
neuron axons have been described following knockdown
of C9orf72 in zebra-fish [2], although more recent stud-
ies in mice have found no effect of complete lack of
C9ORF72 on motor function [15]. Our results demon-
strate the presence of C9ORF72 as puncta throughout
the actin cytoskeleton, and the presence of the protein
in synaptic-rich fractions. There are a number of vesicles
known to be present in axons including those supplying
the synapse, those involved in membrane trafficking and
axon outgrowth, and vesicles containing RNA and sig-
naling vesicles [21]. Membrane trafficking is critical for
cell survival and defects in transport to the membrane are
common hallmarks of neurodegenerative diseases, includ-
ing FTLD [35]. In a similar line, we recently showed that
C9ORF72 is involved in endosomal trafficking via Rab-
dependent pathways [7]. When C9ORF72 expression was
knocked down, endocytosis and autophagy-related traf-
ficking were inhibited. Human C9ORF72 isoforms have
also been shown to interact with nuclear pore complex
components, suggesting a possible role in nucleocytoplas-
mic shuttling [37]. These studies, in combination with our
current results related to synaptosome preparations and
differential nuclear and cytoplasmic localization, may sug-
gest that C9ORF72 plays a role in trafficking and raises
the possibility that failure in such neuronal cellular trans-
port during ageing may be linked to neurodegeneration.
Like many other genetic causes of neurodegenerative
disorders, the repeat expansion found in the C9ORF72
gene is present at birth but does not cause disease until
later in life. If haploinsufficiency of the encoded protein,
C9ORF72, does contribute to disease then this suggests
Fig. 6 Localization of C9ORF72 over development in vitro. Immunofluorescence was carried out on primary cultured cortical neurons. a At 1 DIV,
C9ORF72 (red) labeling was present within cell bodies, excluding nuclei (DAPI, blue) and punctate localization was present in neurites and growth
cones (β-III tubulin, green). b Co-staining with phalloidin (green) at 3 DIV confirmed localization of C9ORF72 (red) labeling to growth cones and to
filopodia (arrows). c At 14 DIV, C9ORF72 (red) was localized to nuclei of a population of neurons (arrows) but was less intensely expressed in nuclei
of other neurons (arrowhead). Neurons indicated by MAP2 (green). Neurons with nuclear immunolabeling for C9ORF72 frequently had punctate
somal localization of this protein. Inset (c) shows C9ORF72 labeling in nuclei and in puncta in surrounding cytoplasm. Scale bar: A, 2.5 μm; B,
C, 10 μm
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that it is due to vulnerability caused by altered isoform
expression in ageing.
This study has been the first to give a detailed descrip-
tion of the expression of C9ORF72 in mice, including ex-
pression over development, and lays a foundation for
future studies examining the effects of altering C9ORF72
expression in rodent models, potentially providing insights
into how abnormal repeat expansion may be associated
with FTLD and ALS. The presence of C9ORF72 within
vesicular puncta also warrants further study. Identification
of these vesicles could be key to determining the role of
this protein within cells.
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Additional files
Additional file 1: Figure S1. Primer efficiency and melting curve
analysis. (a). The efficiency of the primer pairs for C9orf72 isoforms was
assessed by plotting the cycle threshold value (Ct) at each concentration
against the logarithm of the fold dilution of the sample. The slope of a
linear-regression trendline is indicative of primer efficiency. Primer efficiencies
were 1.86 for isoform 1 (a i), 1.94 for isoform 2 (a ii) and 1.97 for isoform
3 (a iii). (b) Representative melting curve analysis showing the specific
amplification of the C9orf72 isoform products. Melting peaks (plotted as
the negative derivative of fluorescence) revealed peaks at three different
temperatures which indicate the identity of amplified C9orf72 isoforms.
(TIFF 24326 kb)
Additional file 2: Figure S2. Preadsorbtion with C9ORF72 peptide. (a)
P56 tissue from C57/Bl6 mice or (b) 7 DIV cortical neurons cultured from
C57/Bl6 mice were labeled with C9ORF72 (sc-138763) antibody or
C9ORF72 (sc-138763) antibody preadsorbed with the C9ORF72 peptide
(sc-138763 P). Labeling was decreased in both preadsorbed samples.
Labeling of puncta (arrows) and nuclei (arrowheads) with C9ORF72
antibody was present in brain tissue and cultured neurons (panel 1, a, b).
In contrast, when labeled with preadsorbed C9ORF72 peptide, there was
no nuclei labeling and non-specific puncta present in brain samples
(arrows, panel 2, a), and in cultured samples there was faint non-specific
nuclear labeling and an absence of puncta (arrowhead, panel 2, b). Scale
bar: a, 12 μm; b, 10 μm. (TIFF 999 kb)
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